Objective-Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Serum amyloid A (SAA) is an acute phase protein and a binding partner for the multiligand receptor for advanced glycation end products (RAGE). We investigated the role of the interaction between SAA and RAGE in uremia-related atherogenesis. Approach and Results-We used a mouse model of uremic vasculopathy, induced by 5 of 6 nephrectomy in the Apoe −/− background. Sham-operated mice were used as controls. Primary cultures of Ager +/+ and Ager −/− vascular smooth muscle cells (VSMCs) were stimulated with recombinant SAA, S100B, or vehicle alone. Relevance to human disease was assessed with human VSMCs. The surface area of atherosclerotic lesions at the aortic roots was larger in uremic Apoe −/− than in sham-operated Apoe −/− mice (P<0.001). Furthermore, atherosclerotic lesions displayed intense immunostaining for RAGE and SAA, with a pattern similar to that of α-SMA. Ager transcript levels in the aorta were 6× higher in uremic animals than in controls (P<0.0001). Serum SAA concentrations were higher in uremic mice, not only after 4 weeks of uremia but also at 8 and 12 weeks of uremia, than in sham-operated animals. We investigated the functional role of RAGE in uremia-induced atherosclerosis further, in animals lacking RAGE. We found that the induction of uremia in Apoe −/− Ager −/− mice did not accelerate atherosclerosis. In vitro, the stimulation of Ager +/+ but not of Ager −/− VSMCs with SAA or S100B significantly induced the production of reactive oxygen species, the phosphorylation of AKT and mitogenactivated protein kinase-extracellular signal-regulated kinases and cell migration. Reactive oxygen species inhibition with N-acetyl cysteine significantly inhibited both the phosphorylation of AKT and the migration of VSMCs. Similar results were obtained for human VSMCs, except that the phosphorylation of mitogen-activated protein kinase-extracellular signal-regulated kinases, rather than of AKT, was subject to specific redox-regulation by SAA and S100B. Furthermore, human aortic atherosclerotic sections were positively stained for RAGE and SAA. Conclusions-Uremia upregulates SAA and RAGE expression in the aortic wall and in atherosclerotic lesions in mice. Ager −/− animals are protected against the uremia-induced acceleration of atherosclerosis. SAA modulates the functions of murine and human VSMCs in vitro in a RAGE-dependent manner. This study, therefore, identifies SAA as a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE.
C ardiovascular disease is the leading cause of death in patients with end-stage renal disease. Uremic patients have a 10× to 20× higher risk of cardiovascular diseaserelated death than individuals from the general population. 1 Uremic vasculopathy is characterized by extensive atherosclerosis and arteriosclerotic lesions. 2 Arterial calcifications of the medial part of vessels are the main feature of the arteriosclerotic lesions. These calcifications are now known to result from an active smooth muscle cell-dependent mineralization process. [3] [4] [5] Serum amyloid A (SAA) proteins constitute a family of acute phase proteins synthesized by the liver in response to cytokines. 6 Serum SAA levels are high in individuals at high risk of cardiovascular disease, suggesting that SAA is a marker of cardiovascular risk. 6 High levels have been reported in uremic patients and are independently associated with cardiovascular mortality. 7 SAA has also been reported to play an active role in the atherogenic process. 6, 8, 9 First, SAA has been detected in the atherosclerotic lesions of hyperlipidemic animals and is produced in situ by vascular cells involved in atherogenesis, such as endothelial cells, smooth muscle cells, and adipocytes. 7, 10 Second, SAA modulates the function of cultured monocytes and macrophages. [11] [12] [13] Toll-like receptors (2 and 4) and the scavenger receptor CD36 have been reported to mediate the effect of SAA in vitro, depending on cell type. 14, 15 Receptor for advanced glycation end products (RAGE) has also been identified as a binding partner for SAA. 7, 12, [16] [17] [18] RAGE is a cell surface receptor of the immunoglobulin superfamily involved in important processes, such as cell migration, adhesion, and proliferation [19] [20] [21] [22] RAGE was first described as a binding partner for AGEs 23, 24 ; however, proteins from the S100 family, amyloid fibrils, high mobility group box 1, C3a, and CpG DNA oligonucleotides can trigger a proinflammatory response via RAGE. 20 RAGE signaling is, therefore, involved in the pathogenesis of several diseases, including diabetes mellitus, cancer, autoimmune disorders, neurodegenerative and vascular diseases. 17, 18, 20, 22, 25, 26 RAGE signaling has been implicated in uremia-induced atherosclerosis. 27, 28 Indeed, in uremic vasculopathy, in addition to the typical risk factors for cardiovascular disease, vascular changes also involve factors related to uremia, such as anemia, hyperphosphatemia, or the accumulation of cytotoxic molecules called uremic toxins. 1, 2, 29 Some of these uremic toxins, such as advanced glycation end products and the S100 family of proteins, exert their effects through interaction with RAGE. 30, 31 Given the strong involvement of RAGE signaling in atherosclerosis and the independent association of high serum levels in uremic patients with cardiovascular mortality, we investigated whether SAA acted as a uremic toxin modulating important smooth muscle cell-dependent disturbances in uremia-related atherogenesis through interaction with RAGE.
Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Uremia Promotes Atherosclerotic Lesions and the Phosphorylation of AKT and MAPK-ERK
We used a previously described mouse model of uremic vasculopathy to analyze the effect of uremia on atherosclerosis and on important signaling pathways. Apoe −/− mice were sham operated or subjected to 5 of 6 nephrectomy to induce uremia. 32, 33 Twelve weeks after surgery, serum, heart valves, and aortas were retrieved from the 2 groups of animals. Serum was used to analyze biochemical variables (Table) . Aorta roots were stained with Oil Red O to measure the surface area of atherosclerotic lesions ( Figure 1A) , and aortas were analyzed by Western blotting ( Figure 1B) .
Consistent with previous studies using the same model of uremic vasculopathy, serum concentrations of total cholesterol and triglycerides were significantly higher in uremic than in sham-operated mice. Uremia also promoted the accumulation of calcium and phosphate in serum (Table) . Furthermore, we confirmed that the surface area of aorta root atherosclerotic lesions was significantly larger in uremic than in shamoperated animals: 54±4.6% versus 30±4.54%, respectively, P<0.001 ( Figure 1A ). We then analyzed the effect of uremia on the aortic phosphorylation of AKT and MAP-kinase ERK. Interestingly, we found that in uremic mice, the phosphorylation levels of both AKT and ERK were twice those in shamoperated mice (P<0.01 and P<0.05, respectively; Figure 1B ).
Uremia Promotes the Expression of SAA and RAGE
We then measured serum concentrations of SAA protein in sham-operated and uremic mice. Circulating levels of SAA were significantly higher in uremic than in sham-operated animals. Four weeks after surgery, uremic animals had mean serum SAA concentration of 436.3±38 versus 4.8±1.6 μg/mL for sham-operated animals (P<0.0001). Twelve weeks after surgery, serum SAA concentrations in uremic animals were lower than those at the 4-week time point, but remained significantly higher in uremic mice than in sham-operated controls (26.2±6.9 versus 11.79±5.72 μg/mL, respectively; P<0.005; Figure 1C ).
Given the involvement of RAGE signaling in the atherosclerotic process, we measured Ager mRNA levels in aortas retrieved from sham-operated and uremic mice. Ager transcript levels were almost 6× higher in uremic than in shamoperated mice (P<0.0001; Figure 1D ).
For confirmation of the upregulation of Ager expression in uremic mice and to analyze the abundance of the SAA protein, we performed immunostaining on aortic arches retrieved from sham-operated and uremic mice. SAA staining was stronger in aortas from uremic mice than in those from control mice. In particular, staining for SAA was intense in the vessel wall and in atherosclerotic plaques ( Figure 2 ). Immunostaining for RAGE was also stronger in aortic tissue from uremic mice than in vessels from control animals. Interestingly, the pattern of staining for α-SMA differed between control and uremic tissues. Uremic tissues were positively stained for α-SMA at the fibrous cap at the periphery of the atherosclerotic lesion, suggesting that this fibrous cap was formed by migrating vascular smooth muscle cells (VSMCs). Furthermore, the periphery of the lesion also stained positive for RAGE and SAA, suggesting that these proteins were also involved in the uremic atherosclerotic process. These results suggest that uremia is associated with an acceleration of atherosclerosis and high levels of both the SAA and the RAGE proteins in atherosclerotic lesions. Furthermore, uremia induces high levels of circulating SAA and the phosphorylation of MAPK ERK and AKT in the aorta.
RAGE Deletion Protects Against the Uremia-Mediated Acceleration of Atherosclerosis
We analyzed the functional role of RAGE in vivo further, by subjecting Apoe −/− Ager −/− mice to sham surgery or 5 of 6 nephrectomy, and then comparing the surface areas of the atherosclerotic lesions in the 2 groups of animals. The areas covered by atherosclerotic lesions did not differ significantly between sham-operated (n=5) and uremic (n=5) Apoe −/− Ager −/− mice (15.8±8.2% and 18.5±7.8%, respectively; Figure 3 ). This suggests that the upregulation of RAGE mRNA and protein levels during uremia is involved in the acceleration of atherosclerosis.
SAA Signals Through RAGE
We hypothesized that the interaction of circulating lipid-free SAA with RAGE expressed on the surface of VSMCs was involved in the uremic atherosclerotic process. We explored the effect of SAA on the functions of primary VSMCs, by investigating the activation of signaling pathways and the production of reactive oxygen species (ROS) in these cells in vitro. We compared the effect of SAA with that of a wellknown ligand of RAGE, S100B. We also used Ager −/− VSMCs to analyze the involvement of RAGE in the effects mediated by SAA.
We stimulated primary cultures of Ager +/+ and Ager −/− VSMCs with exogenous recombinant SAA (200 ng/mL), S100B (20 μg/mL), or vehicle alone and analyzed intracellular signaling. Consistent with previous reports, 18 AKT and MAP kinase ERK were phosphorylated in response to S100B stimulation in Ager +/+ cells. Interestingly, stimulation with SAA induced the intense, rapid, and transient phosphorylation of AKT on Ser473. Mitogen-activated protein kinase-extracellular signalregulated kinases (MAPK-ERK) was also phosphorylated, albeit to a lesser extent, in Ager +/+ cells in response to SAA. By contrast, stimulation of Ager −/− cells with either SAA or S100B had no effect on intracellular signaling ( Figure 4A-4D ). We then measured the production of ROS, using a fluorescent probe ( Figure 4E ). The stimulation of Ager +/+ cells with SAA or S100B resulted in significant production, with mean values of 25.84±0.52 AU for SAA, 44.68±18.2 AU for S100B, and 6.01±0.007 AU for the control (P<0.0001 for SAA and S100B versus control). However, neither SAA nor S100B stimulated the production of ROS in Ager −/− cells: the mean values were 0.001±0.003 AU for SAA, 0.05±0.35 AU for S100B, and 0.05±0.02 AU for the control.
These results suggest that the stimulation of VSMCs with SAA induces RAGE-dependent intracellular signaling, leading to the production of ROS.
SAA Stimulates the RAGE-Dependent Migration of VSMCs
The migration of VSMCs is an important step in the development of atherosclerotic lesions. Therefore, we studied the migration of VSMCs after their stimulation with SAA or S100B ( Figure 5 ).
We used a wound healing migration assay and found that stimulation of Ager +/+ cells with SAA (200 ng/mL) or with S100B (20 μg/mL) for 24 hours significantly promoted the migration of these cells: the numbers of migrating cells were 117±11 for the control, 537±6 in response to SAA (P<0.01), and 312±6 in response to S100B (P<0.001). However, these effectors did not significantly induce the migration of Ager −/− cells ( Figure 5A and 5B).
For confirmation of these results, we evaluated the migration of Ager +/+ and Ager −/− VSMCs in chemotactic chambers. We studied migration toward SAA, S100B, and 20% FBS as a positive control. Both cell types migrated strongly and to a similar extent toward FBS ( Figure 5C ). The stimulation of Ager +/+ primary VSMCs with SAA (200 ng/mL) or S100B (20 μg/L) significantly induced the time-dependent chemotactic migration of these cells. Optical densities, reflecting the number of migrated cells, after 24 hours of incubation were 2.36±0.14 AU for SAA, 1.83±0.15 AU for S100B, and 0.96±0.26 AU for control media (P<0.001 for SAA and S100B versus control; Figure 5C ). However, the stimulation of Ager −/− VSMCs with SAA or S100B did not significantly induce the migration of these cells. Indeed, the optical density after 8 hours of stimulation was 0.71±0.09 AU for SAA, 0.67±0.02 AU for S100B, and 0.79±0.15 AU for control media (nonsignificant) ( Figure 5C ). We then analyzed cell proliferation ( Figure 5D ). We cultured VSMCs in the same conditions used for the migration assay. Neither SAA nor S100B induced the proliferation of Ager +/+ or Ager −/− cells, as shown by comparisons with control cells. Incubation with 20% for 48 hours significantly stimulated proliferation in both Ager +/+ (531±115% of control; P<0.001) and Ager −/− cells (405±62.3% of control; P<0.001; Figure 5D ).
These results suggest that SAA stimulates the migration of VSMCs via RAGE but has no effect on cellular proliferation.
SAA Controls VSMC Migration Through RAGE-Mediated Oxidative Stress
RAGE is a potent inducer of oxidative stress. Indeed, we previously reported that the migration of VSMCs in response to S100B-RAGE depends on the activation of nicotinamide adenine dinucleotide phosphate oxidase. 34 We therefore investigated whether the SAA-RAGE-mediated migration of VSMCs was linked to redox regulation ( Figure 6 ).
We treated cells with 10 nmol/L N-acetyl cysteine (NAC) and analyzed ROS production after stimulation with SAA or S100B. NAC significantly inhibited ROS production in response to SAA (23±0.49 AU in the absence of NAC versus 8.46±0.13 AU in the presence of NAC; P<0.001) or S100B (25.7±0.28 in the absence of NAC versus 8.6±0.12 in the presence of NAC; P<0.001). We then analyzed the signaling pathways induced by SAA and S100B. NAC significantly inhibited the phosphorylation of AKT on ser473 in cells stimulated with SAA or S100B, but had no effect on the phosphorylation of MAPK-ERK. Finally, we investigated the effect of inhibiting oxidative stress on the migration of VSMCs in response to SAA or S100B. NAC significantly inhibited the migration of VSMCs stimulated with SAA or S100B. Indeed, the number of migrating cells after 24 hours of stimulation with SAA was 558±11 cells in the absence of NAC versus 270±15 cells in the presence of NAC. Similarly, the number of migrating cells after 24 hours of stimulation with S100B was 321±10 cells in the absence of NAC versus 94±8 cells in the presence of NAC.
These results suggest that, like S100B, SAA triggers RAGE-dependent oxidative signaling, leading to the migration of VSMCs.
SAA Controls Human VSMC Migration Through RAGE-Mediated Oxidative Stress
We assessed the relevance of our results to human disease, using human VSMCs. The stimulation of human VSMCs with SAA induced the production of significant amounts of ROS (36.5±7.7 versus 7.34±1.93 AU in control stimulated human VSMCs; P<0.0001). By contrast, the coincubation of cells with SAA and NAC significantly inhibited ROS production (17.2±4.16 AU P<0.0001 versus SAA alone; Figure 7A ). Interestingly, a similar effect was observed in migration tests: SAA alone significantly induced human VSMC migration after 24 hours of stimulation (142±45 migrating cells versus 58±23 migrating cells in the control; P<0.01), whereas NAC significantly decreased cell migration (55±35 migrating cells; P<0.01 versus SAA-stimulated cells; Figure 7B ). These results suggest that, like murine VSMCs, human VSMCs can migrate in response to SAA-induced ROS production. We then analyzed the signaling pathways involved and found that, by contrast to our findings for murine VSMCs, human VSMCs predominantly displayed MAPK-ERK phosphorylation in response to SAA and S100B, with no significant induction of AKT ( Figure 7C ). Incubation with NAC significantly inhibited the phosphorylation of MAPK-ERK induced by SAA and S100B. Finally, we analyzed RAGE and SAA expressions in human atherosclerotic lesions. Sections from aneurysmal resections of 6 patients were stained with control isotype antibodies or with antibodies against RAGE or SAA. Staining intensity was scored blindly (0-4 AU). The mean score was 0 AU for the isotype control, 2.5±1.38 AU for SAA, and 1.16±0.75 AU for RAGE. These results suggest that human atherosclerotic tissue expresses both RAGE and SAA, highlighting the potential role of this signaling pathway in human disease.
Discussion
The risk of cardiovascular events increases steadily with declining glomerular filtration rate. 2, [35] [36] [37] Overall, the uremic population has a 10× to 20× higher risk of death caused by cardiovascular complications than the general population. This risk is even higher for younger patients on dialysis (<45 years old), who are 100× more likely to die from a cardiovascular event than age-matched individuals from the general population. Vascular disease in these patients involves arteriosclerotic lesions affecting the medial part of vessels and extensive atherosclerosis. 37 The frequency of traditional cardiovascular risk factors does not fully explain this high mortality rate. Other factors, including some related to uremia, must therefore contribute. SAA is a highly conserved positive acute-phase protein. It is rapidly produced by the liver in response to tissue injury and cytokine release, resulting in a transient but significant increase in its concentration in serum, rising from 1 to 5 μg/mL to 1000 μg/mL in <24 h. About 95% of circulating SAA is reportedly bound to high-density lipoprotein (HDL). SAA production is thought to be a systemic response to tissue injury, which favors the recycling and reuse of body cholesterol, a critical constituent necessary for the generation of the enormous numbers of cells involved in the inflammatory response. 6 However, a pathological role for SAA has been reported in systemic amyloidosis. 16 SAA (isoform 1) binds to the ubiquitous cell surface protein RAGE, 12, 16 stimulating proinflammatory signaling, with the activation of nuclear factor-κB and cellular stress pathways. Ager deletion in a mouse model of SAA-related amyloidosis prevents amyloid deposition in the spleen and nuclear factor-κB activation. 16 Figure 5 . Serum amyloid A (SAA) induces the receptor for advanced glycation end products (RAGE)-dependent migration of vascular smooth muscle cells (VSMCs). A, RAGE +/+ and RAGE −/− VSMCs were seeded onto 6-well plates. At confluence, the cells were incubated with DMEM without FBS for 24 h (starvation). The monolayer was scratched with a sterile pipette tip and cells were exposed to the RAGE-specific ligand S100B (20 μg/mL) or to SAA (200 ng/mL) for 24 h. Images are representative of a wound area after 24 h of treatment. B, The number of migrated cells through the wound is expressed as the mean±SEM; n=7 independent experiments. C, Chemotactic migration assay. RAGE +/+ and RAGE −/− VSMCs were incubated with S100B (20 μg/mL), SAA (200 ng/mL), or 20% FBS for 8 h at 37°C. The migrating cells were then stained and the optical density of the staining reagent was measured at 560 nm using a microplate reader. Results are expressed as the mean±SEM; n=3 independent experiments. D, Proliferation assay: RAGE +/+ and RAGE −/− VSMCs were seeded with S100B (20 μg/mL), SAA (200 ng/mL), or FBS (20%, as positive control) for 24 and 48 h at 37°C. Cell proliferation was then determined by measuring the absorbance emitted by the reduction of WST-1 (cell proliferating reagent WST-1) soluble formazan. Results are expressed as the percentage of proliferating cells compared to the control. **P<0.01; ***P<0.001.
We describe here a new pathological role for SAA. We found that the induction of uremia in mice promoted the formation of atherosclerotic lesions and stimulated the expression of RAGE and SAA. Mice deleted for RAGE were protected against uremia-induced accelerated atherosclerosis. Furthermore, in primary VSMCs, SAA triggered RAGEdependent intracellular signaling, the production of ROS, and cell migration.
We used a well-characterized model of uremic vasculopathy. Indeed, several studies have shown that the induction of uremia in Apoe −/− mice is associated with the appearance of vascular changes, such as atherosclerosis and vascular calcifications. 32, 33 These vascular modifications mimic those of uremic vasculopathy in humans. Our results are not only consistent with these previous reports but also identify SAA and RAGE as potential factors controlling uremia-related vascular modifications.
SAA has been detected in atherosclerotic lesions. 6,10 However, the effect of the circulating lipid-free form of SAA on the development of atherosclerotic lesions was unclear. Lipid binding was thought to be necessary for the biological effect of SAA, 6 but we report here that free SAA may also play an active role in atherosclerosis by modulating the functions of VSMCs in a RAGE-dependent manner. Our results are consistent with those of Dong et al, 38 who reported that the overexpression of free SAA in Apoe −/− animals promoted the development of atherosclerotic lesions in the absence of changes in cholesterol levels. Furthermore, Wilson et al 8 reported that the stimulation of VSMCs with SAA in vitro promoted biglycan synthesis and, consequently, low-density lipoprotein fixation, potentially initiating atherosclerosis. Therefore, both HDL-bound SAA and lipid-free circulating SAA may have pathogenic effects in atherosclerosis.
The receptors potentially involved in the proatherosclerotic effects of SAA have not been extensively studied. A study by Cai et al 12 on freshly isolated peripheral blood monocytes suggested that free circulating SAA interacted with RAGE, leading to the activation of the MAPK kinase ERK and nuclear factor-κB and the secretion of monocyte tissue factor by these cells. Thus, the SAA-RAGE interaction may be critical for inflammation and thrombosis. Similarly, our results suggest that this interaction may be involved in uremia-related atherosclerosis. We cannot determine, with the mouse model used in our study, which cell type is targeted by the SAA-RAGE axis. However, our in vitro results strongly suggest that smooth muscle cells are important in the atherosclerotic process and are modulated by SAA in a RAGE-dependent manner.
In line with our results, we could speculate that the inhibition or invalidation of SAA could slow down the atherosclerotic process. Interestingly, De Beer et al 39 negative results did not imply that SAA was not involved in atherosclerotic process, but merely that SAA deletion was not sufficient to stop the atherosclerotic process. These findings should be analyzed in terms of the effect of RAGE invalidation in the same genetic background. Indeed, Harja et al 26 reported that ApoE −/− mice produced larger amounts of RAGE ligands, such as S100 proteins and AGEs, and also increased expression of RAGE. The invalidation of RAGE in this animal model was associated with a significant reduction of atherosclerotic lesion surface area. 26 These observations, therefore, suggest that SAA invalidation alone may not be sufficient to inhibit RAGE signaling, and that a more profound protective effect is obtained when the multiligand receptor RAGE is invalidated than through the isolated invalidation of individual ligands. RAGE signaling has been implicated in atherosclerosis and in vascular complications, but its involvement in uremiarelated vascular changes has not been widely investigated. 27 However, RAGE ligands do accumulate in the context of uremia and are correlated with cardiovascular mortality. 31, 40, 41 Moreover, Bro et al 27 reported that the administration of anti-RAGE antibodies limited uremia-induced atherosclerois in mice. RAGE promotes the migration of various cell types. 18, 25 Here, we found that the SAA-RAGE interaction was important for the migration of VSMCs in vitro. Furthermore, we previously showed that the oxidative stress was a key mechanism by which RAGE mediated its effects. 25, 34 This study supports the view that RAGE-mediated oxidative stress is important for the regulation of VSMC migration, thereby highlighting the link between RAGE and oxidative stress. Our results suggest a possible role for the SAA-RAGE interaction in the pathophysiology of uremic atherosclerosis. Our data appear to be relevant to human atherosclerosis. Additional studies should, therefore, be performed to highlight the role of the interaction between SAA and RAGE interaction for future therapeutic approaches.
We also found that serum SAA levels were higher in the first few weeks of uremia than at later time points, suggesting that the proatherogenic effect of SAA may occur during early phases of the atherosclerotic process. This is consistent with the results of Krishack et al 42 for ldlr −/− mice. They found that SAA invalidation in this genetic background was associated with a reduction of atherosclerosis after 6 weeks of a high-fat diet, with no further difference after 12 weeks. This suggests that SAA may be involved in the early phases of atherosclerosis.
Uremia is characterized by the retention of various solutes that would normally be excreted by the kidneys. 29, 43 Those able to interfere with biological functions are called uremic toxins. About 80 substances have been identified as toxins, including advanced glycation end products, such as carboxymethyl lysine and pentosidine, which interact with their specific receptor, RAGE. 44 In this study, we focused on the proatherogenic effect of SAA via interaction with RAGE, but the triggering of this receptor by other uremia-related ligands cannot be excluded.
Interestingly, chronic moderately high plasma SAA levels have been reported in uremic patients. 7 Furthermore, proteomic analyses of the HDL cholesterol retrieved from these patients have revealed that higher levels of SAA are bound to HDL cholesterol in these patients than in healthy individuals. 45 The same authors also showed that the HDL isolated from uremic patients reduced cholesterol efflux from macrophages and reduced the expression of anti-inflammatory molecules by these cells. 45 These results suggest that, in uremic conditions, SAA binding to HDL cholesterol may regulate cholesterol efflux and atherogenesis. Our findings suggest that SAA has a proatherogenic role during uremia. SAA accumulated in the plasma of uremic mice and exogenous lipid-free SAA modulated the functions of VSMCs in a RAGE-dependent manner in vitro in this study. Additional studies will be required to determine the pathological concentrations of SAA in the sera of uremic patients, the potential link to cardiovascular mortality and to confirm the biological effects of SAA mediated by interaction with RAGE. Nonetheless, this study identifies SAA as a potential new uremic toxin involved in uremic atherosclerosis and RAGE as an important actor in the development of uremic vasculopathy.
